[HTML] cell.com

[HTML][HTML] A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC

K Du, Y Li, J Liu, W Chen, Z Wei, Y Luo, H Liu, Y Qi… - Molecular Therapy, 2021 - cell.com
Glypican-3 (GPC3) is a well-characterized hepatocellular carcinoma (HCC)-associated
antigen, yet anti-GPC3 therapies have achieved only minimal clinical progress. CD47 is a …
被引用次数：82 相关文章

A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC

K Du, Y Li, J Liu, W Chen, Z Wei… - … therapy: the journal …, 2021 - pubmed.ncbi.nlm.nih.gov
Glypican-3 (GPC3) is a well-characterized hepatocellular carcinoma (HCC)-associated
antigen, yet anti-GPC3 therapies have achieved only minimal clinical progress. CD47 is a …
[HTML] sciencedirect.com

[HTML][HTML] A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC

K Du, Y Li, J Liu, W Chen, Z Wei, Y Luo, H Liu, Y Qi… - Molecular Therapy, 2021 - Elsevier
Glypican-3 (GPC3) is a well-characterized hepatocellular carcinoma (HCC)-associated
antigen, yet anti-GPC3 therapies have achieved only minimal clinical progress. CD47 is a …
[HTML] nih.gov

[HTML][HTML] A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC

K Du, Y Li, J Liu, W Chen, Z Wei, Y Luo, H Liu… - Molecular …, 2021 - ncbi.nlm.nih.gov
Abstract Glypican-3 (GPC3) is a well-characterized hepatocellular carcinoma (HCC)-
associated antigen, yet anti-GPC3 therapies have achieved only minimal clinical progress …

A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC.

K Du, Y Li, J Liu, W Chen, Z Wei, Y Luo… - … Therapy: the Journal …, 2021 - europepmc.org
Abstract Glypican-3 (GPC3) is a well-characterized hepatocellular carcinoma (HCC)-
associated antigen, yet anti-GPC3 therapies have achieved only minimal clinical progress …